mizoribine has been researched along with Familial Spastic Paraparesis, Htlv-1-Associated in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arimura, K; Higuchi, I; Izumo, S; Kawabata, M; Kubota, H; Maruyama, Y; Nakagawa, M; Nakahara, K; Osame, M | 1 |
| Arimura, K; Higuchi, I; Hokezu, Y; Inose, M; Izumo, S; Osame, M; Yoshimine, K | 1 |
2 trial(s) available for mizoribine and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antiviral Agents; Ascorbic Acid; Azathioprine; Danazol; Erythromycin; Estrogen Antagonists; Female; Fosfomycin; Glycerol; Human T-lymphotropic virus 1; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Immunosuppressive Agents; Injections, Intramuscular; Injections, Intravenous; Injections, Spinal; Interferon-gamma; Leukapheresis; Male; Methylprednisolone; Middle Aged; Paraparesis, Tropical Spastic; Pentoxifylline; Plasmapheresis; Propiophenones; Respiratory Therapy; Ribonucleosides; Sulfasalazine; Thyrotropin-Releasing Hormone; Vasodilator Agents | 1996 |
[A study of clinical symptoms, muscle pathology, therapeutic response, and prognosis of myositis in patients with HTLV-1 associated myelopathy (HAM)].
Topics: Adult; Aged; Anti-Inflammatory Agents; Atrophy; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Muscle, Skeletal; Myositis; Necrosis; Paraparesis, Tropical Spastic; Prednisolone; Prognosis; Ribonucleosides; Treatment Outcome | 1999 |